Amgen Inc. said a regimen of Kyprolis (carfilzomib), melphalan and prednisone failed to extend median progression-free survival for newly diagnosed multiple myeloma patients beyond what's delivered by a similar regimen anchored instead by Takeda Oncology Co.'s Velcade (bortezomib).